Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan China and quickly caused an outbreak that spread around the world. The virus causes a severe acute respiratory syndrome with its disease designated as COVID-19. As of November 2021, more than 5 million deaths from COVID19 have been confirmed, making it one of the worst pandemics in known history.
This pandemic has impacted immunocompromised patients significantly more than the general population and caused higher morbidity and mortality. SARS-CoV2 vaccines have been developed quickly and proven effective in preventing serious infections, but immunocompromised patients are less responsive to standard vaccine protocols.
The goal of this Research Topic “SARS-CoV-2 Infection and COVID-19 Disease in immunocompromised hosts” is to cover aspects related to 1) basic research in human and animal models and 2) translational research in immunophenotyping and biomarkers development focusing on response to vaccine in immunocompromised hosts. We will focus on multiple organ transplant recipients. We will also include the impact of immune-modulating biologics on COVID-19 severity and vaccine response.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan China and quickly caused an outbreak that spread around the world. The virus causes a severe acute respiratory syndrome with its disease designated as COVID-19. As of November 2021, more than 5 million deaths from COVID19 have been confirmed, making it one of the worst pandemics in known history.
This pandemic has impacted immunocompromised patients significantly more than the general population and caused higher morbidity and mortality. SARS-CoV2 vaccines have been developed quickly and proven effective in preventing serious infections, but immunocompromised patients are less responsive to standard vaccine protocols.
The goal of this Research Topic “SARS-CoV-2 Infection and COVID-19 Disease in immunocompromised hosts” is to cover aspects related to 1) basic research in human and animal models and 2) translational research in immunophenotyping and biomarkers development focusing on response to vaccine in immunocompromised hosts. We will focus on multiple organ transplant recipients. We will also include the impact of immune-modulating biologics on COVID-19 severity and vaccine response.